An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels

Experimental Neurology

Volumn 223, Issue 2, 2010, Pages 432-438

  Petzold, A ^a,e   Chapman, M D ^a   Schraen, S ^b   Verwey, N A ^e   Pasquier, F ^c   Bombois, S ^c   Brettschneider, J ^d   Fox, N C ^a   von Arnim, C A F ^d   Teunissen, C ^e   Pijnenburg, Y ^e   Riepe, M W ^d   Otto, M ^d   Tumani, H ^d   Scheltens, P ^e   Buee, L ^b   Rossor, M N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSERM   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF ULM   (Germany)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cerebrospinal fluid; CSF; Dementia; Tau

Indexed keywords

TAU PROTEIN;

ACCURACY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

AGED; ALZHEIMER DISEASE; BENCHMARKING; CHEMISTRY, CLINICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY CONTROL; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAU PROTEINS;

EID: 77952551434     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.11.010     Document Type: Article

References (64)

1. Andreasen N., Vanmechelen E., Van de Voorde A., Davidsson P., Hesse C., Tarvonen S., Raiha I., Sourander L., Winblad B., Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J. Neurol. Neurosurg. Psychiatry 1998, 64:298-305.
2. Andreasen N., Minthon L., Clarberg A., Davidsson P., Gottfries J., Vanmechelen E., Vanderstichele H., Winblad B., Blennow K. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999, 53:1488-1494.
3. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C.M., Lee V.M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann. Neurol. 1995, 38:649-652.
4. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Matsushita S., Machida N., Nakagawa T., Lee V., Trojanowski J., Sasaki H. Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease. J. Am. Geriatr. Soc. 1997, 45:1228-1231.
5. Arai H., Satoh-Nakagawa T., Higuchi M., Morikawa Y., Miura M., Kawakami H., Seki H., Takase S., Sasaki H. No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia. Neurosci. Lett. 1998, 256:174-176.
6. Bian H., Swieten J.C.V., Leight S., Massimo L., Wood E., Forman M., Moore P., de Koning I., Clark C.M., Rosso S., Trojanowski J., Lee V.M.-Y., Grossman M. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008, 70(19 Pt 2):1827-1835. May.
7. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2:605-613.
8. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Mol. Chem. Neuropathol. 1995, 26:231-245.
9. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., Lijmer J.G., Moher D., Rennie D., de Vet H.C.W. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326(7379):41-44. for Reporting of Diagnostic Accuracy, S, Jan.
10. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., Andreasen N., Hofmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttila T., Schapiro M.B., Rapoport S.I., Moller H.J., Davies P., Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 2002, 59:1267-1272.
11. Burger nee Buch K., Padberg F., Nolde T., Teipel S.J., Stubner S., Haslinger A., Schwarz M.J., Sunderland T., Arai H., Rapoport S.I., Moller H.J., Hampel H. Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. Neurosci. Lett. 1999, 277:21-24.
12. Deisenhammer, F., Egg, R., Giovanni, G., Hemmer, B., Petzold, A., Sellebjerg, F., Teunissen, C., Tumani, H., 2009. EFNS guidelines on disease specific CSF investigations. Eur. J. Neurol. 16, 760-770.
13. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6(8):734-746.
14. Galasko D., Clark C., Chang L., Miller B., Green R., Motter R., Seubert P. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997, 48:605-632.
15. Green A.J. Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. Neuropathol. Appl. Neurobiol. 2002, 28:427-440.
16. Green A.J., Harvey R.J., Thompson E.J., Rossor M.N. Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neurosci. Lett. 1999, 259:133-135.
17. Growden J.H. Consensus report of the working group on: "Molecular and biochemical markers of Alzheimer's disease". Neurobiol. Aging 1998, 19:109-116.
18. Hampel H., Teipel S.J., Padberg F., Haslinger A., Riemenschneider M., Schwarz M.J., Kotter H.U., Scheloske M., Buch K., Stubner S., Dukoff R., Lasser R., Muller N., Sunderland T., Rapoport S.I., Moller H.J. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. Brain Res. 1999, 823:104-112.
19. Hu Y., He S., Wang X., Duan Q., Grundke-Iqbal I., Iqbal K., Wang J. Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol. 2002, 160:1269-1278.
20. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., Vanderstichele H. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 1999, 52:1555-1562.
21. Ishiguro K., Ohno H., Arai H., Yamaguchi H., Urakami K., Park J.M., Sato K., Kohno H., Imahori K. Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease. Neurosci. Lett. 1999, 270:91-94.
22. Kahle P., Jakowec M., Teipel S., Hampel H., Petzinger G., Di Monte D., Silverberg G., Moller H., Yesavage J., Tinklenberg J., Shooter E., Murphy G.M. Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology 2000, 54:1498-1904.
23. Kanai M., Matsubara E., Isoe K., et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann. Neurol. 1998, 44:17-26.
24. Kanemaru K., Kameda N., Yamanouchi H. Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 2000, 54:1875-1876.
25. Kapaki E., Kilidireas K., Paraskevas G.P., Michalopoulou M., Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?. J. Neurol. Neurosurg. Psychiatry 2001, 71:401-403.
26. Kapaki E., Paraskevas G.P., Zalonis I., Zournas C. CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population. Eur. J. Neurol. 2003, 10:119-128.
27. Kurz A., Riemenschneider M., Buch K., Willoch F., Bartenstein P., Muller U., Guder W. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1998, 12:372-377.
28. Lewczuk P., Beck G., Ganslandt O., Esselmann H., Deisenhammer F., Regeniter A., Petereit H., Tumani H., Gerritzen A., Oschmann P., Schroder J., Schonknecht P., Zimmermann K., Hampel H., Burger K., Otto M., Haustein S., Herzog K., Dannenberg R., Wurster U., Bibl M., Maler J., Reubach U., Kornhuber J., Wiltfang J. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 2006, 409:1-4.
29. Martinez M., Fernandez E., Frank A., Guaza C., de la Fuente M., Hernanz A. Increased cerebrospinal fluid cAMP levels in Alzheimer's disease. Brain Res. 1999, 846:265-267.
30. Maruyama M., Arai H., Sugita M., Tanji H., Higuchi M., Okamura N., Matsui T., Higuchi S., Matsushita S., Yoshida H., Sasaki H. Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease. Exp. Neurol. 2001, 172:433-436.
31. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.-K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosén E., Aarsland D., Visser P.J., Schröder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Pirttilä T., Wallin A., Jönhagen M.E., Minthon L., Winblad B., Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302(4):385-393. Jul.
32. McKeith I. Clinical Lewy body syndromes. Ann. N. Y. Acad. Sci. 2000, 920:1-8.
33. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
34. Morikawa Y., Arai H., Matsushita S., Kato M., Higuchi S., Miura M., Kawakami H., Higuchi M., Okamura N., Tashiro M., Matsui T., Sasaki H. Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics. Alcohol. Clin. Exp. Res. 1999, 23:575-577.
35. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., et a. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 1995, 38:608-643.
36. Mulder C., Schoonenboom S., Wahlund L., Scheltens P., van Kamp G., Veerhuis R., Hack C., Blomberg M., Schutgens R., Eikelenboom P. CSF markers related to pathogenetic mechanisms in Alzheimer's disease. J. Neural Transm. 2002, 109:1408-1491.
37. Neary D., Snowden J., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P., Albert M., Boone K., Miller B., Cummings J., Benson D. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998, 51:1546-1554.
38. Nishimura T., Takeda M., Shinosaki K., Nishikawa T., Nakamura Y., Yoshida Y., Sasaki H., Arai H., Hirai S., Shouji M., Isse K., Tanaka K., Hamamoto M., Yamamoto H., Matsubayashi T., Nakashima K., Urakami K., Adachi Y., Nakamura S., Toji H., Yoshida H. Basic and clinical studies on ApoE gene typing by line probe assay (LiPA) as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan. Methods Find. Exp. Clin. Pharmacol. 1998, 20:793-799.
39. Petzold A. CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurol. Res. 2007, 29:691-708.
40. Petzold A. Biomarker for early diagnosis of Alzheimer's disease. The CSF analysis in dementia 2008, 123-156. NOVA Science Publishers, Inc., New York, Ch. 1st Ed.
41. Petzold, A., Chapman, M., Keir, G., Baker, S., Warren, J., Fox, N., Rossor, M., 6 Jun. 2007. CSF proteins in dementia diagnosis, national Audit day. The National Hospital for Neurology and Neurosurgery, Queen Square, London.
42. Ransohoff D.F., Feinstein A.R. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N. Engl. J. Med. 1978, 299(17):926-930. Oct.
43. Riemenschneider M., Buch K., Schmolke M., Kurz A., Guder W. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci. Lett. 1996, 212:209-211.
44. Riemenschneider M., Wagenpfeil S., Diehl J., Lautenschlager N., Theml T., Heldmann B., Drzezga A., Jahn T., Forstl H., Kurz A. Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 2002, 58:1622-1628.
45. Roman G.C. Defining dementia: clinical criteria for the diagnosis of vascular dementia. Acta Neurol. Scand. Suppl. 2002, 178:6-9.
46. Rosler N., Wichart I., Jellinger K.A. Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 1996, 60:237-238.
47. Rosler N., Wichart I., Jellinger K.A. Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients. J. Neural Transm. 2001, 108:231-246.
48. Schonknecht P., Pantel J., Hunt A., Volkmann M., Buerger K., Hampel H., Schroder J. Levels of total tau and tau protein phosphorylated at threonine 181 in patients with incipient and manifest Alzheimer's disease. Neurosci. Lett. 2003, 339:172-174.
49. Shoji M., Matsubara E., Kanai M., Watanabe M., Nakamura T., Tomidokoro Y., Shizuka M., Wakabayashi K., Igeta Y., Ikeda Y., Mizushima K., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., Hirai S. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J. Neurol. Sci. 1998, 158:134-140.
50. Shoji M., Matsubara E., Murakami T., Manabe Y., Abe K., Kanai M., Ikeda M., Tomidokoro Y., Shizuka M., Watanabe M., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., Nishimura T., Nakamura Y., Takeda M., Urakami K., Adachi Y., Nakashima K., Arai H., Sasaki H., Kanemaru K., Yamanouchi H., Yoshida Y., Ichise K., Tanaka K., Hamamoto M., Yamamoto H., Matsubayashi T., Yoshida H., Toji H., Nakamura S., Hirai S. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol. Aging 2002, 23:363-370.
51. Sjogren M., Minthon L., Davidsson P., Granerus A..K., Clarberg A., Vanderstichele H., Vanmechelen E., Wallin A., Blennow K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural Transm. 2000, 107:563-579.
52. Sjogren M., Rosengren L., Minthon L., Davidsson P., Blennow K., Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000, 54:1960-1964.
53. Sjogren M., Davidsson P., Gottfries J., Vanderstichele H., Edman A., Vanmechelen E., Wallin A., Blennow K. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process. Dement. Geriatr. Cogn. Disord. 2001, 12:257-264.
54. Sjogren M., Davidsson P., Tullberg M., Minthon L., Wallin A., Wikkelso C., Granerus A., Vanderstichele H., Vanmechelen E., Blennow K. Both total and phosphorylated tau are increased in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2001, 70:624-630.
55. Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., Skoog I., Wallin A., Wahlund L., Marcusson J., Nagga K., Andreasen N., Davidsson P., Vanmechelen E., Blennow K. Tau and A-beta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin. Chem. 2001, 47:1776-1781.
56. Sjogren M., Davidsson P., Wallin A., Granerus A., Grundstrom E., Askmark H., Vanmechelen E., Blennow K. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 2002, 13:108-112.
57. Solberg H.E. International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values, and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved Recommendation (1986) on the theory of reference values. Part 1. The concept of reference values. J. Clin. Chem. Clin. Biochem. 1987, 25:337-342.
58. Sunderland T., Wolozin B., Galasko D., Levy J., Dukoff R., Bahro M., Lasser R., Motter R., Lehtimaki T., Seubert P. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psychiatry 1999, 46:705-750.
59. Tapiola T., Lehtovirta M., Ramberg J., Helisalmi S., Linnaranta K., Riekkinen P., Soininen H. CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease. Neurology 1998, 50:169-174.
60. Vanderstichele H., Blennow K., D'Heuvaert N.D., et al. CSF: progress in Alzheimer's and Parkinson's diseases. Development of a specific diagnostic test for measurement of beta-amyloid(1-42) 1998, 773-778. Plenum Press, New York, Ch.
61. Vanderstichele H., De Meyer G., Shaprio F., Engelborghs S., De Deyn P., Shaw L., Trojanowski J. Biomarkers for early diagnosis of Alzheimer's disease. Alzheimer's disease biomarkers: from concept to clinical utility 2008, 81-122. Nova Science Publishers, Inc., New York, Ch. 1st. Ed.
62. van der Zee J., Sleegers K., Broeckhoven C.V. Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum. Neurology 2008, 71(15):1191-1197. Oct.
63. Verwey, N., van der Flier, W., Blennow, K., Clark, C., Sokolow, S., De Deyn, P., Galasko, D., Hampel, H., Hartmann, T., Kapaki, E., Lannfelt, L., Mehta, P., Parnetti, L., Petzold, A., Pirttila, T., Saleh, L., Skinningsrud, A., v. Swieten, J., Verbeek, M., Wiltfang, J., Younkin, S., Scheltens, P., Blankenstein, M., 2009. A worldwide multicenter comparison of assays for CSF biomarkers in Alzheimer disease. Ann. Clin. Biochem. 46, 235-240.
64. Waldemar G., Dubois B., Emre M., Georges J., McKeith I.G., Rossor M., Scheltens P., Tariska P., Winblad B. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 2007, 14:e1-e26.